JP2024505577A5 - - Google Patents

Info

Publication number
JP2024505577A5
JP2024505577A5 JP2023547066A JP2023547066A JP2024505577A5 JP 2024505577 A5 JP2024505577 A5 JP 2024505577A5 JP 2023547066 A JP2023547066 A JP 2023547066A JP 2023547066 A JP2023547066 A JP 2023547066A JP 2024505577 A5 JP2024505577 A5 JP 2024505577A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
seq
substitution
acid position
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023547066A
Other languages
English (en)
Japanese (ja)
Other versions
JP7745640B2 (ja
JP2024505577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015116 external-priority patent/WO2022169975A1/en
Publication of JP2024505577A publication Critical patent/JP2024505577A/ja
Publication of JP2024505577A5 publication Critical patent/JP2024505577A5/ja
Priority to JP2025153139A priority Critical patent/JP2026001001A/ja
Application granted granted Critical
Publication of JP7745640B2 publication Critical patent/JP7745640B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547066A 2021-02-03 2022-02-03 抗体およびその使用 Active JP7745640B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153139A JP2026001001A (ja) 2021-02-03 2025-09-16 抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145348P 2021-02-03 2021-02-03
US63/145,348 2021-02-03
PCT/US2022/015116 WO2022169975A1 (en) 2021-02-03 2022-02-03 Anti-met antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153139A Division JP2026001001A (ja) 2021-02-03 2025-09-16 抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2024505577A JP2024505577A (ja) 2024-02-06
JP2024505577A5 true JP2024505577A5 (cg-RX-API-DMAC7.html) 2025-02-12
JP7745640B2 JP7745640B2 (ja) 2025-09-29

Family

ID=80448813

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547066A Active JP7745640B2 (ja) 2021-02-03 2022-02-03 抗体およびその使用
JP2025153139A Pending JP2026001001A (ja) 2021-02-03 2025-09-16 抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153139A Pending JP2026001001A (ja) 2021-02-03 2025-09-16 抗体およびその使用

Country Status (28)

Country Link
US (2) US20240141065A1 (cg-RX-API-DMAC7.html)
EP (2) EP4288456B1 (cg-RX-API-DMAC7.html)
JP (2) JP7745640B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230136758A (cg-RX-API-DMAC7.html)
CN (1) CN117529499A (cg-RX-API-DMAC7.html)
AU (2) AU2022218165B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023015050A2 (cg-RX-API-DMAC7.html)
CA (1) CA3209786A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002272A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023010689A2 (cg-RX-API-DMAC7.html)
DK (1) DK4288456T3 (cg-RX-API-DMAC7.html)
ES (1) ES2998692T3 (cg-RX-API-DMAC7.html)
FI (1) FI4288456T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241544T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069371T2 (cg-RX-API-DMAC7.html)
IL (1) IL304686A (cg-RX-API-DMAC7.html)
LT (1) LT4288456T (cg-RX-API-DMAC7.html)
MX (1) MX2023009146A (cg-RX-API-DMAC7.html)
PE (1) PE20250153A1 (cg-RX-API-DMAC7.html)
PL (1) PL4288456T3 (cg-RX-API-DMAC7.html)
PT (1) PT4288456T (cg-RX-API-DMAC7.html)
RS (1) RS66266B1 (cg-RX-API-DMAC7.html)
SA (1) SA523450167B1 (cg-RX-API-DMAC7.html)
SI (1) SI4288456T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400476T1 (cg-RX-API-DMAC7.html)
TW (1) TW202246335A (cg-RX-API-DMAC7.html)
WO (1) WO2022169975A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307404B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220053577A (ko) * 2019-07-30 2022-04-29 마이틱 테라퓨틱스, 인크. 항원 결합 단백질 작제물 및 이의 용도
CN117529499A (zh) 2021-02-03 2024-02-06 神话治疗股份有限公司 抗met抗体和其用途
KR20250122502A (ko) 2022-12-11 2025-08-13 마이틱 테라퓨틱스, 인크. 항-cMET 항체 약물 접합체 및 이의 치료적 용도
WO2025245128A1 (en) 2024-05-20 2025-11-27 Mythic Therapeutics, Inc. Antibody drug conjugates and therapeutic uses thereof
WO2026112478A1 (en) 2024-11-24 2026-05-28 Mythic Therapeutics, Inc. Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CN102174106B (zh) 2011-03-17 2013-04-10 朱进 抗Met人源Fab及其阿霉素偶联物和其制法及应用
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
KR20160069363A (ko) * 2014-12-08 2016-06-16 삼성전자주식회사 항체 선별 방법
SG11201705988UA (en) 2015-02-24 2017-08-30 Bioatla Llc Conditionally active biological proteins
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
KR20180104148A (ko) 2016-02-05 2018-09-19 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
RS61659B1 (sr) * 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
MX2019002199A (es) 2016-08-31 2019-05-16 Bioatla Llc Polipeptidos condicionalmente activos y métodos para generarlos.
EP3519440A4 (en) 2016-09-29 2020-03-25 Mitsubishi Tanabe Pharma Corporation MONOCLONAL CMET BINDERS, ACTIVE SUBSTANCE CONJUGATES AND USES THEREOF
US20210283249A1 (en) 2016-11-16 2021-09-16 Eli Lilly And Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
DK3544634T3 (da) 2016-11-23 2021-06-07 Lilly Co Eli MET-antistof-lægemiddelkonjugater
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met抗體以及其免疫結合物及用途
JP2020518240A (ja) 2017-01-17 2020-06-25 ザ テキサス エー アンド エム ユニバーシティー システム 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
CA3044082A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
MX2020010110A (es) * 2018-03-28 2020-11-06 Mitsubishi Tanabe Pharma Corp Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
KR20220053577A (ko) 2019-07-30 2022-04-29 마이틱 테라퓨틱스, 인크. 항원 결합 단백질 작제물 및 이의 용도
CN117529499A (zh) 2021-02-03 2024-02-06 神话治疗股份有限公司 抗met抗体和其用途
KR20250122502A (ko) 2022-12-11 2025-08-13 마이틱 테라퓨틱스, 인크. 항-cMET 항체 약물 접합체 및 이의 치료적 용도

Similar Documents

Publication Publication Date Title
US20210095047A1 (en) PSMA Targeting Trispecific Proteins and Methods of Use
JP2024513244A5 (cg-RX-API-DMAC7.html)
CN106414498B (zh) TNF α的结合成员
JP2022543771A5 (cg-RX-API-DMAC7.html)
US10428156B2 (en) Anti-MFI2 antibodies and methods of use
US20180243435A1 (en) Anti-dll3 antibody drug conjugates and methods of use
KR102345173B1 (ko) 증가된 안정성을 가진 인간화 항체
US20170044271A1 (en) Novel anti-dpep3 antibodies and methods of use
CN103319599B (zh) 一种抗人ErbB2抗体—美登木素偶联物及其应用
EP3297672A1 (en) Trispecific binding proteins and methods of use
WO2015164392A2 (en) Novel antii-rnf43 antibodies and methods of use
EP3107576A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
JP2016116536A5 (cg-RX-API-DMAC7.html)
US20160257756A1 (en) Antibodies against ccr9 and applications thereof
FI4288456T3 (fi) Anti-met-vasta-aineita ja niiden käyttöjä
US20210261670A1 (en) Novel anti-bmpr1b antibodies and methods of use
Muguruma et al. Novel Hybrid Compound of a Plinabulin Prodrug with an IgG Binding Peptide for Generating a Tumor Selective Noncovalent-Type Antibody–Drug Conjugate
Benjamini et al. Immunochemical studies on the tobacco mosaic virus protein. VI. Characterization of antibody populations following immunization with tobacco mosaic virus protein
CN111315779A (zh) 抗-cd3抗体及包含其的用于癌症治疗的药物组合物
JP2019511199A (ja) 新規の抗upk1b抗体及び使用方法
CN113512090A (zh) 一种颗粒酶b结合化合物及其前体化合物和用途
US20190016812A1 (en) Novel anti-tnfsf9 antibodies and methods of use
CA2758751C (en) Antibodies against prostate specific membrane antigen
JP2025181917A5 (cg-RX-API-DMAC7.html)
JPS63501502A (ja) スクリーニングおよび処理方法